Drug-drug interaction study to assess the effects of atorvastatin co-administration on pharmacokinetics and anti-thrombotic properties of cilostazol in male Wistar rats

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 8, 2012, Pages 455-465

  Vats, Rahul ^a   Varanasi, Kanthikiran V S ^b   Arla, Rambabu ^b   Veeraraghvan, Sridhar ^b   Rajak, Shraddha ^b  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b Glenmark Pharmaceuticals Limited   (India)

Author keywords

anti thrombotic effect; atorvastatin; cilostazol; drug drug interaction; Wistar rat

Indexed keywords

ATORVASTATIN; CILOSTAZOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; AREA UNDER THE CURVE; ARTERY OCCLUSION; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DRUG INTERACTION; DRUG METABOLISM; DRUG PENETRATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; METABOLIC INHIBITION; NONHUMAN; RAT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; WISTAR RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BLEEDING TIME; CAROTID ARTERIES; DRUG INTERACTIONS; FIBRINOLYTIC AGENTS; HEPTANOIC ACIDS; INTESTINAL ABSORPTION; MALE; MICROSOMES, LIVER; PLATELET AGGREGATION; PYRROLES; RATS; RATS, WISTAR; TETRAZOLES;

EID: 84867896064     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1812     Document Type: Article

References (41)

1. Schrör K,. The pharmacology of cilostazol. Diabetes Obes Metab 2002; 4: S14-S19.
2. Hirsch AT, Criqui MH, Treat-Jacobson D, et al,. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 19: 1317-1324.
3. Ji X, Hou M,. Novel agents for anti-platelet therapy. J Hematol Oncol 2011; 4: 44.
4. Hiatt WR,. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-1621.
5. Liu Y, Shakur Y, Kambayashi J,. Phosphodiesterases as targets for intermittent claudication. Handb Exp Pharmacol 2011; 204: 211-236.
6. Elam MB, Heckman J, Crouse JR, et al,. Effect of the novel anti-platelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998; 18: 1942-1947.
7. Akiyama H, Kudo S, Shimizu T,. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneimittelforschung 1985; 35: 1133-1140.
8. Abbas R, Chow CP, Browder NJ, et al,. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol 2000; 19: 178-184.
9. http://www.rxlist.com/pletal-drug.htm [18 July 2012].
10. Bramer SL, Forbes WP, Mallikaarjun S,. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet 1999; 37: 1-11.
11. Akiyama H, Kudo S, Shimizu T,. The absorption, distribution and excretion of a new anti thrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Arzneimittelforschung 1985; 35: 1124-1132.
12. Toyobuku H, Tamai I, Ueno K, Tsuji A,. Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug. J Pharm Sci 2003; 92: 2249-2259.
13. Williams D, Feely J,. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-370.
14. Gaddam V, Li DY, Mehta JL,. Anti-thrombotic effects of atorvastatin-an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther 2002; 7: 247-253.
15. Radulovic LL, Cilla DD, Posvar EL, Sedman AJ, Whitefield LR,. Effect of food on the bio-availability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 1995; 35: 990-994.
16. Lau YY, Okochi H, Huang Y, Benet LZ,. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 2006; 34: 1175-1181.
17. Lennernas H,. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003; 42: 1141-1160.
18. Black AE, Hayes RN, Roth BD, Woo P, Woolf TF,. Metabolism and excretion of atorvastatin between rats and dogs. Drug Metab Dispos 1999; 27: 916-923.
19. Le Couteur DG, Martin PT, Bracs P, et al,. Metabolism and excretion of [14C]-atorvastatin in patients with T-tube drainage. Proc Aust Soc Clin Exp Pharmacol Toxicol 1996; 3: 153.
20. Hochman JH, Pudvah N, Qiu J, et al,. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res 2004; 21: 1686-1691.
21. Boyd RA, Stern RH, Stewart BH, et al,. Atorvastatin co-administration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40: 91-98.
22. Suri A, Forbes WP, Bramer SL,. Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet 1999; 37: 61-68.
23. Reinoso RF, Sanchez Navarro A, Garcia MJ, Prous JR,. Pharmacokinetic interactions of statins. Methods Find Exp Clin Pharmacol 2001; 23: 541.
24. Pletal tablets 100 mg. Patient information leaflet distributed by Otsuka Pharmaceuticals Ltd (UK). http://www.mhra.gov.uk/home/groups/pla/documents/ websiteresources /con020797.pdf [20 July 2012].
25. Mitropoulos KA, Balasubramaniam S,. Cholesterol 7α-hydrolase in rat liver microsomal preparations. Biochem J 1972; 128: 1-9.
26. Smith PK, Krohn RI, Hermanson GT, et al,. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85.
27. Ravi PR, Vats R, Thakur R, Srivani S, Aditya N,. Effect of grapefruit juice and ritonavir on pharmacokinetics of lopinavir in Wistar rats. Phytother Res 2012. DOI: 10.1002/ptr.4593.
28. Vats R, Varanasi KK, Arla R, et al,. Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats. J Pharm Pharmacol 2012. doi: 10.1111/j.2042-7158.2012.01542.x.
29. Kurz KD, Main BW, Sandusky GE,. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-280.
30. Bednar B, Condra C, Gould RJ, Connolly TM,. Platelet aggregation monitored in a 96 well microplate reader is useful for evaluation of platelet agonists and antagonists. Thromb Res 1995; 77: 453-463.
31. Varanasi KK, Sridhar V, Potharaju S, et al,. Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 865: 91-98.
32. Food and Drug Administration (FDA). Guidance for Industry: Bio Analytical Method Validation. U.S. Department of Health and Human Services: Rockville, 2001.
33. Kamada N, Yamada K, Odomi M, et al,. Sex differences in pharmacokinetics of cilostazol in rats. Xenobiotica 2011; 41: 903-913.
34. Bramer SL, Forbes WP,. Relative bio-availability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin Pharmacokinet 1999; 37: 13-23.
35. Manaster BJ, Manaster S,. Techniques for estimating allometric equations. J Morphol 1975; 147: 299-307.
36. Takara K, Ohnishi N, Horibe S, Yokoyama T,. Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily m-RNAS in small intestine. Drug Metab Dispos 2003; 31: 1235-1239.
37. Christians U, Schmitz V, Haschke M,. Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol 2005; 1: 641-654.
38. Patel SG, Rajput SJ,. Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes. AAPS PharmSciTech 2009; 10: 660-669.
39. Prueksaritanont T, Subramanian R, Fang X, et al,. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002; 30: 505-512.
40. Clarke TA, Waskell LA,. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31: 53-59.
41. Gresele P, Momi S, Falcinelli E,. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 2011; 72: 634-646.